Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by KPOIndustrieson Nov 01, 2019 8:01am
117 Views
Post# 30296108

RE:Quote from Q2.

RE:Quote from Q2.
SAGDollar wrote: "The Company has initiated a contract with a large health system to improve patient compliance with cancer screening. The details of this contract are confidential between the parties and cannot be disclosed at this time.We have been very open about the fact that we are in discussion with several large health groups and have been anticipating engaging with one or more of them to improve patient compliance with screening for cancer. We are extremely pleased with the direction this relationship has taken and look forward to being able to share the results of the initiative when it is suitable for all parties involved, said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. Hopefully we can get some clarification on this deal in the near future. The anticipation is real and I think that Oncore deal is just the beginning. Been slowly accumulating this week and hoping that Q3 shows a increase of test volume.. A couple more weeks to go

I could not say this better. Any investor that has been here since the early portion of 2019 is aware of the significant developments StageZero has made. I am confident test numbers , if not already significantly increased, will turn the bend and lead to brighter days for this stock. There is SO MUCH going on that the company has touched on but not fully announced that it is just a matter of time until SP reflects what the company is all about. The technology speaks for itself and the avenue in which we are headed is exciting. StageZero is ganing presence in Europe and North America. Tripp has mentioned that there are a lot of similar deals they are working on. This is something to be excited about. I am optiomistic for solid Q3 numbers and a GREEN holiday season!! Good luck all and happy FRIDAY!!!
Bullboard Posts